Download MendeleySmall molecule inhibitors of mannan-binding lectin-associated serine Proteases-2 and-3.
Nakhla, M.C., Comita, J., Shapiro, A.B., Moussa, S.H., Chen, A., Eyermann, C.J., O'Donnell, J.P., Miller, A.A., Granger, B.A.(2025) Eur J Med Chem 289: 117238-117238
- PubMed: 40010268 Search on PubMed
- DOI: https://doi.org/10.1016/j.ejmech.2025.117238
- Primary Citation Related Structures:
9D17, 9D3Y, 9D40, 9D4D - PubMed Abstract:
The complement system of innate immunity recognizes, opsonizes, and kills invading pathogens and damaged cells, and stimulates an inflammatory response. Inappropriate or excessive complement activity is associated with a wide variety of pathological conditions, and several drugs targeting complement components have been approved. Here we describe the discovery and structure-activity relationships of a novel class of 2-aminoimidazole-containing inhibitors of mannan-binding lectin-associated serine proteases -2 and -3 (MASP-2 and MASP-3), essential enzymes for activation of the lectin and alternative pathways of complement, respectively. With a high degree of target selectivity and favorable in vitro pharmacological properties, this inhibitor series has the potential to be developed as treatments for numerous diseases and pathological conditions.
- Innoviva Specialty Therapeutics, Inc., Waltham, MA, 02451, USA.
Organizational Affiliation:
